Alissa J. Cooper, MD

In this final segment, Dr. Sands asks Dr. Cooper to discuss how subcutaneous administration of targeted therapies may influence clinical practice in EGFR-mutated non-small cell lung cancer.

In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that these agents are designed to target the TROP2 antigen on tumor cells and deliver a cytotoxic payload, enabling selective tumor cell killing.

In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung cancer.

In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase inhibitor and chemotherapy, now with new brain metastases.

In this segment, Dr. Sands asks Dr. Wakelee how she discusses toxicity profiles and treatment burden with patients when selecting first-line therapy for EGFR-mutated non-small cell lung cancer.

Dr Cooper discusses recent advances that have reshaped the treatment paradigm for small cell lung cancer, particularly in the relapsed setting.

In this case-based segment, Dr. Sands presents a patient scenario involving a 64-year-old never-smoker with EGFR-mutated metastatic non-small cell lung cancer and asymptomatic brain metastases.

In this segment, Dr. Sands asks Dr. Cooper to discuss the role of intracranial efficacy in guiding first-line treatment decisions for EGFR-mutated non-small cell lung cancer.

In this case-based segment, Dr. Sands presents a patient scenario involving a 64-year-old never-smoker with EGFR-mutated metastatic non-small cell lung cancer and asymptomatic brain metastases

In this segment, Dr. Sands asks Dr. Wakelee to discuss the role of value-based frameworks in evaluating first-line treatment options for EGFR-mutated non-small cell lung cancer.

In this segment, Dr. Sands asks Dr. Cooper to discuss the evolving role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Cooper explains that these agents are designed to deliver cytotoxic payloads directly to tumor cells by targeting TROP2, a surface antigen expressed in many epithelial cancers, thereby enhancing antitumor activity while attempting to limit off-target effects.

In this segment, Dr. Sands asks the panel to reflect on how emerging data presented at recent meetings, including ELCC, are influencing treatment strategies in EGFR-mutated non-small cell lung cancer.

In this segment, Dr. Sands invites the panel to discuss how subcutaneous administration may influence treatment experience in EGFR-mutated non-small cell lung cancer, referencing data from the PALOMA-3 trial.

In this segment, Dr. Sands leads a discussion on how clinicians approach risk–benefit assessment in EGFR-mutated non-small cell lung cancer as newer combination strategies become available.

In this segment, Dr. Sands invites Dr. Cooper to explain how she evaluates key efficacy outcomes in selecting first-line therapy for EGFR-mutated non-small cell lung cancer, emphasizing the importance of integrating progression-free survival, overall survival, CNS activity, and patient-specific factors to guide individualized, real-world treatment decisions.

In this opening segment, Dr. Sands invites the panel to outline the current treatment landscape for EGFR-mutated non-small cell lung cancer, with Dr. Wakelee and Dr. Cooper highlighting how recent advances, including data from key phase III trials, are shaping first-line decisions, balancing monotherapy and combination strategies, and integrating efficacy, CNS activity, and tolerability into real-world clinical practice.

Panelists discuss how the next 3 to 5 years will likely see T-cell engagers moving into earlier treatment lines, potential ADCs replacing chemotherapy in first-line therapy, and the critical need for better biomarker testing to optimize treatment sequencing and patient selection in an increasingly complex therapeutic landscape.

Panelists discuss how emerging therapies including DLL3-targeted ADCs, trispecific T-cell engagers, CAR T cells, and radioligand therapies represent promising approaches that may offer single-dose treatments or enhanced efficacy, though more data on durability and optimal sequencing are needed.

Panelists discuss how antibody-drug conjugates targeting B7-H3 show impressive response rates compared to historical controls, while T-cell engagers remain the priority for second-line therapy due to their demonstrated durability, though patient preferences and contraindications may influence individual treatment decisions.

Panelists discuss how tarlatamab implementation requires careful infrastructure planning, including 24-hour monitoring capabilities, staff education about cytokine release syndrome management, patient counseling, and coordination with community partners to ensure all eligible patients have access to this standard-of-care therapy.

Panelists discuss how neutropenia management varies widely across institutions, with some using primary prophylaxis with G-CSF or trilaciclib, while others tailor supportive care based on individual patient risk factors including age, comorbidities, and prior treatment tolerance.

Panelists discuss how monitoring for long-term immunotherapy toxicities requires regular imaging and symptom assessment, with early recognition and treatment of pneumonitis, hypothyroidism, and adrenal insufficiency being critical for maintaining patients on therapy and preventing chronic complications.

Panelists discuss how managing toxicities during chemoradiation requires proactive counseling about esophagitis and fatigue, while immunotherapy consolidation typically doesn’t enhance these acute toxicities, making it feasible to start within the recommended timeframe after completion of chemoradiation.

Panelists discuss how preliminary neoadjuvant chemoimmunotherapy data showing high response rates and pathologic complete responses in limited-stage SCLC appears promising but requires larger studies and careful patient selection given the complexity of staging and surgical candidacy.

Panelists discuss how while emerging biomarkers like inflamed subtypes and MHC class I expression show promise for predicting immunotherapy benefit, current clinical practice treats all patients with immunotherapy since the potential for exceptional responses cannot be reliably predicted.

Panelists discuss how the concerning underutilization of first-line chemoimmunotherapy in extensive-stage SCLC may stem from clinical nihilism, lack of urgency in treatment initiation, and inadequate education about the substantial benefits these therapies provide to patients.

Panelists discuss how pneumonitis risk management requires intensive patient education about symptoms, close monitoring for several months post radiation, and multidisciplinary coordination with pulmonology and radiation oncology teams to distinguish between radiation-induced and immunotherapy-related pneumonitis.

Panelists discuss how patient selection for durvalumab consolidation requires careful consideration of autoimmune diseases, baseline lung function, and neurologic paraneoplastic syndromes, while emphasizing that most patients should receive immunotherapy unless they have severely active contraindications.

Panelists discuss how durvalumab consolidation after chemoradiation has become the standard of care for limited-stage SCLC based on the ADRIATIC trial, with most patients being considered candidates for the 2-year treatment course.

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.